{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:29:30Z","timestamp":1768004970726,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding (Interdepartmental Clinical Research Project of Peking University First Hospital).","award":["2022CR30"],"award-info":[{"award-number":["2022CR30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04701-8","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T15:02:45Z","timestamp":1704898965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2430-6517","authenticated-orcid":false,"given":"Ming-Zhu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-456X","authenticated-orcid":false,"given":"Xiao-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Shu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Ying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"13","key":"4701_CR1","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1245\/s10434-012-2499-8","volume":"19","author":"M Rink","year":"2012","unstructured":"Rink M, Sjoberg D, Comploj E et al (2012) Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 19(13):4337\u20134344. https:\/\/doi.org\/10.1245\/s10434-012-2499-8","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"4701_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30(10):1107\u20131113. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979","journal-title":"J Clin Oncol"},{"issue":"4","key":"4701_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/annonc\/mds583","volume":"24","author":"A Bamias","year":"2013","unstructured":"Bamias A, Dafni U, Karadimou A et al (2013) Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine\/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16\/03). Ann Oncol 24(4):1011\u20131017. https:\/\/doi.org\/10.1093\/annonc\/mds583","journal-title":"Ann Oncol"},{"issue":"3","key":"4701_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00345-016-1885-4","volume":"35","author":"MN Pham","year":"2017","unstructured":"Pham MN, Apolo AB, De Santis M et al (2017) Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World J Urol 35(3):367\u2013378. https:\/\/doi.org\/10.1007\/s00345-016-1885-4","journal-title":"World J Urol"},{"issue":"6","key":"4701_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970\u2013976. https:\/\/doi.org\/10.1093\/annonc\/mdz127","journal-title":"Ann Oncol"},{"key":"4701_CR6","doi-asserted-by":"crossref","unstructured":"Iwamoto H, Izumi K, Shimura Y et al (2016) Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res 36(10):5557\u20135561","DOI":"10.21873\/anticanres.11140"},{"issue":"3","key":"4701_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.21037\/tau-19-624","volume":"9","author":"T Muilwijk","year":"2020","unstructured":"Muilwijk T, Akand M, Van der Aa F et al (2020) Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Translat Androl Urol 9(3):1296\u20131305. https:\/\/doi.org\/10.21037\/tau-19-624","journal-title":"Translat Androl Urol"},{"issue":"1","key":"4701_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"issue":"6","key":"4701_CR9","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.21037\/tau-20-1466","volume":"9","author":"Q Wei","year":"2020","unstructured":"Wei Q, He H, Lv L et al (2020) The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review. Translat Androl Urol 9(6):2821\u20132830. https:\/\/doi.org\/10.21037\/tau-20-1466","journal-title":"Translat Androl Urol"},{"key":"4701_CR10","doi-asserted-by":"crossref","unstructured":"Ikeda M, Matsumoto K, Niibe Y et al (2011) The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. J Radiat Res 52 (5):674\u2013679","DOI":"10.1269\/jrr.11036"},{"issue":"10185","key":"4701_CR11","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England) 393(10185):2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet (London, England)"},{"issue":"3 Suppl","key":"4701_CR12","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO et al (2010) Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76(3 Suppl):S3\u2013S9. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4701_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M et al (2021) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79(1):62\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.042","journal-title":"Eur Urol"},{"issue":"2","key":"4701_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","volume":"4","author":"JP Sfakianos","year":"2021","unstructured":"Sfakianos JP, Gul Z, Shariat SF et al (2021) Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur Urol Oncol 4(2):170\u2013179. https:\/\/doi.org\/10.1016\/j.euo.2020.12.007","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"4701_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bju.15324","volume":"128","author":"SM Esagian","year":"2021","unstructured":"Esagian SM, Khaki AR, Diamantopoulos LN et al (2021) Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196\u2013205. https:\/\/doi.org\/10.1111\/bju.15324","journal-title":"BJU Int"},{"issue":"3","key":"4701_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","volume":"25","author":"F Audenet","year":"2019","unstructured":"Audenet F, Isharwal S, Cha EK et al (2019) Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 25(3):967\u2013976. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2039","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4701_CR17","doi-asserted-by":"publisher","first-page":"75.e71","DOI":"10.1016\/j.urolonc.2020.06.010","volume":"39","author":"X Li","year":"2021","unstructured":"Li X, Li S, Chi Z et al (2021) Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urol Oncol 39(1):75.e71-75.e78. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.010","journal-title":"Urol Oncol"},{"issue":"7","key":"4701_CR18","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21037\/tau-21-291","volume":"10","author":"M-Z Liu","year":"2021","unstructured":"Liu M-Z, Gao X-S, Qin S-B et al (2021) Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma. Translat Androl Urol 10(7):2929\u20132937. https:\/\/doi.org\/10.21037\/tau-21-291","journal-title":"Translat Androl Urol"},{"issue":"2","key":"4701_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyz152","volume":"50","author":"T Abe","year":"2020","unstructured":"Abe T, Minami K, Harabayashi T et al (2020) Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol 50(2):206\u2013213. https:\/\/doi.org\/10.1093\/jjco\/hyz152","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"4701_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124(2):687\u2013695. https:\/\/doi.org\/10.1172\/JCI67313","journal-title":"J Clin Invest"},{"issue":"5","key":"4701_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD et al (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18(5):313\u2013322. https:\/\/doi.org\/10.1038\/nrc.2018.6","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"4701_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/PPO.0000000000000210","volume":"22","author":"ED Brooks","year":"2016","unstructured":"Brooks ED, Schoenhals JE, Tang C et al (2016) Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer J 22(4):257\u2013266. https:\/\/doi.org\/10.1097\/PPO.0000000000000210","journal-title":"Cancer J"},{"issue":"3","key":"4701_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","volume":"96","author":"SM Hiniker","year":"2016","unstructured":"Hiniker SM, Reddy SA, Maecker HT et al (2016) A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys 96(3):578\u2013588. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.07.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4701_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.radonc.2017.08.009","volume":"125","author":"Y An","year":"2017","unstructured":"An Y, Jiang W, Kim BYS et al (2017) Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80\u201388. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.009","journal-title":"Radiother Oncol"},{"issue":"7","key":"4701_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895\u2013903. https:\/\/doi.org\/10.1016\/S1470-2045(17)30380-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"4701_CR26","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","volume":"7","author":"S Chmura","year":"2021","unstructured":"Chmura S, Winter KA, Robinson C et al (2021) Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 Phase 1 Trial. JAMA Oncol 7(6):845\u2013852. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0687","journal-title":"JAMA Oncol"},{"issue":"2","key":"4701_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","volume":"16","author":"ED Brooks","year":"2019","unstructured":"Brooks ED, Chang JY (2019) Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 16(2):123\u2013135. https:\/\/doi.org\/10.1038\/s41571-018-0119-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4701_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19(1):816. https:\/\/doi.org\/10.1186\/s12885-019-5977-6","journal-title":"BMC Cancer"},{"issue":"5","key":"4701_CR29","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Vandekerkhove G, Decaestecker K et al (2019) Randomized Phase 1 Trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 75(5):707\u2013711. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.009","journal-title":"Eur Urol"},{"key":"4701_CR30","doi-asserted-by":"publisher","unstructured":"Kim JK, Moon KC, Jeong CW et al (2017) Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol https:\/\/doi.org\/10.1016\/j.urolonc.2017.02.010","DOI":"10.1016\/j.urolonc.2017.02.010"},{"issue":"6","key":"4701_CR31","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","volume":"203","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Parizi MK et al (2020) Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis. J Urol 203(6):1075\u20131084. https:\/\/doi.org\/10.1097\/JU.0000000000000523","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04701-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04701-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:17:46Z","timestamp":1735852666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04701-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4701"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04701-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the institutional ethical committee of Peking University First Hospital (No. 2022-097).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"23"}}